Table 6.
Application of chitosan in protein vaccines and polypeptide vaccines.
| Chitosan Complex | Protein/Polypeptide | Immune Mode | Target Disease |
|---|---|---|---|
| Chitosan-modified silica NPs [104] | Bovine serum albumin | Oral | Not mentioned |
| Chitosan NPs [175] | Salmonella enteritidis outer membrane proteins (OMPs) and flagellin proteins | Oral | Brucellosis |
| Chitosan NPs [181] | Fusogenic protein p10 of avian reovirus (ARV-p10) | Intramuscular injection | Melanoma |
| Mannosylated chitosan NPs [176] | FliC antigen | Subcutaneous injection | Brucellosis |
| N-2-Hydroxypropyl trimethyl ammonium chloride chitosan [39] | Porcine parvovirusVP2 protein | Intramuscular injection | Porcine parvovirus disease |
| Mannose-conjugated chitosan [182] | SwIAV antigen | Intranasal | Swine influenza |
| Chitosan [183] | Recombinant protein Pac | Oral | Dental caries |
| Chitosan polymeric NPs [179] | P10 peptide | Intranasal | Paracoccidioidomycosis |
| Chitosan–PLGA NPs [184] | rOmp22 peptide | Subcutaneous injection | Acinetobacter baumannii |
| Trimethyl chitosan [178] | A. streptococcus peptide | Intranasal | Group A Streptococcus |
| Alginate/chitosan/alginate microcapsules [185] | Probiotic expressing M cell homing peptide | Oral | Not mentioned |
| Alginate–chitosan–PLGA complex [186] | Ac-PLP-BPI-NH2-2 peptide | Subcutaneous injection | Autoimmune encephalomyelitis |
| Alginate and trimethyl chitosan [187] | Lipopeptide | Oral | Group A Streptococcus |
| Trimethyl Chitosan NPs [188] | Malaria antigens | Intramuscular injection | Malaria |
| Chitosan [189] | Receptor-binding domain (RBD) polypeptides | Subcutaneous injection | SARS-CoV-2 |
| Chitosan-mannose NPs [190] | Recombinant Art v 1 wormwood pollen protein | Intramuscular, subcutaneous, subcutaneous injection | Allergic bronchial asthma |